Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Maruho’s Rozex in Line for Rosacea Nod in Japan
May 9, 2022
-
BUSINESS Astellas Logs 1st Sales Growth in 3 Years in FY2021; Chairman Hatanaka to Bow Out
April 28, 2022
-
REGULATORY Japan Panel OKs Second Booster for Age 60-Plus, and High-Risk Adults
April 28, 2022
-
REGULATORY Novavax COVID-19 Jab OK’ed for 1st to 3rd Shot Use under Free Program
April 28, 2022
-
ORGANIZATION JPMA Think Tank Analyzing Cause of Expanding Drug Lag, Over 70% of US/EU Approved Meds Not Available in Japan
April 27, 2022
-
BUSINESS Japan Drug Makers Revving Up HR, Pay System Reforms; Eisai Mulling No Daily Allowance for Sales Reps
April 27, 2022
-
BUSINESS Sumitomo Scraps Daily Allowance for Sales Reps, Introduces Division Bonus to Boost Productivity
April 26, 2022
-
BUSINESS Chugai’s Q1 Sales Double on Ronapreve Bonanza, Brisk Hemlibra Export
April 26, 2022
-
REGULATORY Japan Panel OKs Comirnaty, Spikevax for 4th Shot, Use Limited to High-Risk People
April 26, 2022
-
REGULATORY SCARDA Provost Confident about Japanese Technologies, Wants to Mediate Company Matching
April 25, 2022
-
BUSINESS MSD Japan’s Sales Surge 7.5% in 2021, 1.5% Growth If Lagevrio Excluded: President
April 22, 2022
-
BUSINESS GSK Japan Chief Has High Hopes for Shingrix, Blenrep, RSV Jab as Future Growth Drivers
April 21, 2022
-
BUSINESS Lumakras, Bimzelx, Pivlaz Now Available in Japan
April 21, 2022
-
BUSINESS Post-Azilva, Takeda Set to Morph into Rare Disease Specialty Pharma in Japan
April 20, 2022
-
REGULATORY SCARDA Chief Sees First 5 Years as Critical, Japan-Made mRNA Jabs as Initial Work
April 19, 2022
-
REGULATORY Japan Approves Novavax’s COVID-19 Vaccine; Distribution to Start in Late May
April 19, 2022
-
REGULATORY Novavax COVID-19 Vaccine Clears MHLW Panel, Approval Expected Soon
April 19, 2022
-
COMMENTARY Ukraine War Sheds Light on Vulnerabilities in Pharmaceutical Supply Chains in Emergencies
April 19, 2022
-
REGULATORY Emergency Approval Plan Clears Lower House Panel; Opposition Bills Rejected, but Some Ideas Make It into Resolution
April 18, 2022
-
BUSINESS Bayer Yakuhin Sees 2021 Sales Skid 0.6% but Still Reach Target, Retains Spot in Top 10
April 15, 2022
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…